A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

Phase 1 Completed 37 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab

Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 9 days, excluding screening.

Timeline

Start: 2018-12-19
Primary completion: 2019-08-07
Completion: 2019-08-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selpercatinib	Small molecule	160 mg	Oral

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

Summary

Timeline

Drugs

Indications